Jason Zemcik, Senior Director, Product Management

The introduction of increasingly high-cost specialty drugs combined with wider availability of manufacturer co-pay offers has created an opportunity for ill-intentioned pharmacies to financially exploit manufacturer programs, often to the extent of millions of dollars in fraudulent claims.

In this webcast, we will explore trends in fraud tactics and characteristics that place a program at higher risk, why data alone isn’t the answer to fighting co-pay program fraud and best practices for developing an effective investigation and audit capability.